Quantitative proteomics and phosphoproteomics on serial tumor biopsies from a sorafenib-treated HCC patient

Proceedings of the National Academy of Sciences of the United States of America

Volumn 113, Issue 5, 2016, Pages 1381-1386

  Dazert, Eva ^a   Colombi, Marco ^a   Boldanova, Tujana ^b   Moes, Suzette ^a   Adametz, David ^c   Quagliata, Luca ^b   Roth, Volker ^c   Terracciano, Luigi ^b   Heim, Markus H ^b   Jenoe, Paul ^a   Hall, Michael N ^a  

^a UNIVERSITY OF BASEL   (Switzerland)

^b UNIVERSITY HOSPITAL BASEL   (Switzerland)

^c UNIVERSITY OF BASEL   (Switzerland)

Author keywords

EMT; Evasive resistance; Liver; MAPK; Signal transduction

Indexed keywords

ALPHA CATENIN; ALPHA FETOPROTEIN; ANDROSTANOLONE; CASPASE ACTIVATED DEOXYRIBONUCLEASE; DESMOPLAKIN; ENOLASE; FIBRONECTIN; FILAMIN A; FRUCTOSE BISPHOSPHATE ALDOLASE; GLUTAMATE AMMONIA LIGASE; GLYPICAN 3; HEAT SHOCK PROTEIN 70; INITIATION FACTOR 4B; ISOCITRATE DEHYDROGENASE; JUNCTIONAL ADHESION MOLECULE; OXOGLUTARATE DEHYDROGENASE; PLAKOGLOBIN; PROTEIN P120; PROTEIN ZO1; PYRUVATE KINASE; S6 KINASE; SORAFENIB; SUCCINATE DEHYDROGENASE; VIMENTIN; VITRONECTIN; ANTINEOPLASTIC AGENT; CARBANILAMIDE DERIVATIVE; NICOTINAMIDE; PHOSPHOPROTEIN;

ADULT; ADVANCED CANCER; ALPHA FETOPROTEIN BLOOD LEVEL; ANDROGEN METABOLISM; ARTICLE; ASCITES; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER RESISTANCE; CANCER SIZE; CASE REPORT; CELL ADHESION; CELL PROLIFERATION; CITRIC ACID CYCLE; CONTROLLED STUDY; DOWN REGULATION; DRUG WITHDRAWAL; ENZYME PHOSPHORYLATION; EPITHELIAL MESENCHYMAL TRANSITION; FOLLOW UP; GLYCOLYSIS; HEMOCHROMATOSIS; HUMAN; HUMAN TISSUE; IMMUNE RESPONSE; LIVER BIOPSY; LIVER CELL CARCINOMA; LYSOSOME; MALE; MIDDLE AGED; NUTRIENT AVAILABILITY; ONCOGENE C MYC; PHOSPHOPROTEOMICS; PORTAL VEIN OBSTRUCTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEOMICS; PYRIMIDINE SYNTHESIS; QUANTITATIVE ANALYSIS; SIGNAL TRANSDUCTION; TREATMENT DURATION; TUMOR BIOPSY; TUMOR INVASION; UPREGULATION; ANALOGS AND DERIVATIVES; BIOPSY; CARCINOMA, HEPATOCELLULAR; LIVER NEOPLASMS; METABOLISM; PATHOLOGY; PHOSPHORYLATION;

ANTINEOPLASTIC AGENTS; BIOPSY; CARCINOMA, HEPATOCELLULAR; HUMANS; LIVER NEOPLASMS; NIACINAMIDE; PHENYLUREA COMPOUNDS; PHOSPHOPROTEINS; PHOSPHORYLATION; PROTEOMICS;

EID: 84956613798     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1523434113     Document Type: Article

References (54)

1. Yang JD, Roberts LR (2010) Hepatocellular carcinoma: A global view. Nat Rev Gastroenterol Hepatol 7(8):448-458
2. Mazzanti R, Gramantieri L, Bolondi L (2008) Hepatocellular carcinoma: Epidemiology and clinical aspects. Mol Aspects Med 29(1-2):130-143
3. Llovet JM, et al.; SHARP Investigators Study Group (2008) Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359(4):378-390
4. Wilhelm SM, et al. (2004) BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 64(19):7099-7109
5. Bergers G, Hanahan D (2008) Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer 8(8):592-603
6. Carlo-Stella C, et al. (2013) Sorafenib inhibits lymphoma xenografts by targeting MAPK/ERK and AKT pathways in tumor and vascular cells. PLoS One 8(4):e61603
7. Escudier B, et al.; TARGET Study Group (2007) Sorafenib in advanced clear-cell renalcell carcinoma. N Engl J Med 356(2):125-134
8. Masuda M, et al. (2014) Alternative mammalian target of rapamycin (mTOR) signal activation in sorafenib-resistant hepatocellular carcinoma cells revealed by arraybased pathway profiling. Mol Cell Proteomics 13(6):1429-1438
9. Chen KF, et al. (2011) Activation of phosphatidylinositol 3-kinase/Akt signaling pathway mediates acquired resistance to sorafenib in hepatocellular carcinoma cells. J Pharmacol Exp Ther 337(1):155-161
10. van Malenstein H, et al. (2013) Long-term exposure to sorafenib of liver cancer cells induces resistance with epithelial-to-mesenchymal transition, increased invasion and risk of rebound growth. Cancer Lett 329(1):74-83
11. Zhai B, et al. (2014) Inhibition of Akt reverses the acquired resistance to sorafenib by switching protective autophagy to autophagic cell death in hepatocellular carcinoma. Mol Cancer Ther 13(6):1589-1598
12. Li N, et al. (2009) Proteomic analysis of differentially expressed proteins in hepatitis B virus-related hepatocellular carcinoma tissues. J Exp Clin Cancer Res 28:122-132
13. Li C, et al. (2004) Accurate qualitative and quantitative proteomic analysis of clinical hepatocellular carcinoma using laser capture microdissection coupled with isotopecoded affinity tag and two-dimensional liquid chromatography mass spectrometry. Mol Cell Proteomics 3(4):399-409
14. Ai J, et al. (2006) Proteome analysis of hepatocellular carcinoma by laser capture microdissection. Proteomics 6(2):538-546
15. Bao H, et al. (2009) Quantitative proteomic analysis of a paired human liver healthy versus carcinoma cell lines with the same genetic background to identify potential hepatocellular carcinoma markers. Proteomics Clin Appl 3(6):705-719
16. Baker ES, et al. (2014) Advancing the high throughput identification of liver fibrosis protein signatures using multiplexed ion mobility spectrometry. Mol Cell Proteomics 13(4):1119-1127
17. Sun W, et al. (2007) Proteome analysis of hepatocellular carcinoma by twodimensional difference gel electrophoresis: Novel protein markers in hepatocellular carcinoma tissues. Mol Cell Proteomics 6(10):1798-1808
18. Xu B, et al. (2014) Large-scale proteome quantification of hepatocellular carcinoma tissues by a three-dimensional liquid chromatography strategy integrated with sample preparation. J Proteome Res 13(8):3645-3654
19. Luk JM, et al. (2006) Proteomic profiling of hepatocellular carcinoma in Chinese cohort reveals heat-shock proteins (Hsp27, Hsp70, GRP78) up-regulation and their associated prognostic values. Proteomics 6(3):1049-1057
20. Long J, et al. (2010) Glutamine synthetase as an early marker for hepatocellular carcinoma based on proteomic analysis of resected small hepatocellular carcinomas. Hepatobiliary Pancreat Dis Int 9(3):296-305
21. Liu Y, et al. (2014) The role of von Willebrand factor as a biomarker of tumor development in hepatitis B virus-associated human hepatocellular carcinoma: A quantitative proteomic based study. J Proteomics 106:99-112
22. Megger DA, et al. (2013) Proteomic differences between hepatocellular carcinoma and nontumorous liver tissue investigated by a combined gel-based and label-free quantitative proteomics study. Mol Cell Proteomics 12(7):2006-2020
23. Guo T, et al. (2015) Rapid mass spectrometric conversion of tissue biopsy samples into permanent quantitative digital proteome maps. Nat Med 21(4):407-413
24. Monetti M, Nagaraj N, Sharma K, Mann M (2011) Large-scale phosphosite quantification in tissues by a spike-in SILAC method. Nat Methods 8(8):655-658
25. Zanivan S, et al. (2013) In vivo SILAC-based proteomics reveals phosphoproteome changes during mouse skin carcinogenesis. Cell Reports 3(2):552-566
26. Schweppe DK, Rigas JR, Gerber SA (2013) Quantitative phosphoproteomic profiling of human non-small cell lung cancer tumors. J Proteomics 91:286-296
27. Song C, et al. (2011) Improvement of the quantification accuracy and throughput for phosphoproteome analysis by a pseudo triplex stable isotope dimethyl labeling approach. Anal Chem 83(20):7755-7762
28. Narumi R, et al. (2012) A strategy for large-scale phosphoproteomics and SRM-based validation of human breast cancer tissue samples. J Proteome Res 11(11):5311-5322
29. Zanivan S, et al. (2008) Solid tumor proteome and phosphoproteome analysis by high resolution mass spectrometry. J Proteome Res 7(12):5314-5326
30. Harsha HC, Pandey A (2010) Phosphoproteomics in cancer. Mol Oncol 4(6):482-495
31. Geiger T, Cox J, Ostasiewicz P, Wisniewski JR, Mann M (2010) Super-SILAC mix for quantitative proteomics of human tumor tissue. Nat Methods 7(5):383-385
32. Kettenbach AN, Gerber SA (2011) Rapid and reproducible single-stage phosphopeptide enrichment of complex peptide mixtures: Application to general and phosphotyrosine- specific phosphoproteomics experiments. Anal Chem 83(20):7635-7644
33. Di Tommaso L, et al. (2009) The application of markers (HSP70 GPC3 and GS) in liver biopsies is useful for detection of hepatocellular carcinoma. J Hepatol 50(4):746-754
34. Matallanas D, et al. (2011) Raf family kinases: Old dogs have learned new tricks. Genes Cancer 2(3):232-260
35. McCubrey JA, et al. (2007) Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. Biochim Biophys Acta 1773(8):1263-1284
36. Mendoza MC, Er EE, Blenis J (2011) The Ras-ERK and PI3K-mTOR pathways: Cross-talk and compensation. Trends Biochem Sci 36(6):320-328
37. Hauge C, Frodin M (2006) RSK and MSK in MAP kinase signaling. J Cell Sci 119(Pt 15): 3021-3023
38. Fiandalo MV, Wilton J, Mohler JL (2014) Roles for the backdoor pathway of androgen metabolism in prostate cancer response to castration and drug treatment. Int J Biol Sci 10(6):596-601
39. Dozmorov MG, et al. (2010) Elevated AKR1C3 expression promotes prostate cancer cell survival and prostate cell-mediated endothelial cell tube formation: Implications for prostate cancer progression. BMC Cancer 10:672-688
40. Ishizaki F, et al. (2013) Androgen deprivation promotes intratumoral synthesis of dihydrotestosterone from androgen metabolites in prostate cancer. Sci Rep 3:1528-1537
41. Lévesque É, et al. (2013) Molecular markers in key steroidogenic pathways, circulating steroid levels, and prostate cancer progression. Clin Cancer Res 19(3):699-709
42. Oda S, Fukami T, Yokoi T, Nakajima M (2015) A comprehensive review of UDPglucuronosyltransferase and esterases for drug development. Drug Metab Pharmacokinet 30(1):30-51
43. Yeh SH, Chen PJ (2010) Gender disparity of hepatocellular carcinoma: The roles of sex hormones. Oncology 78(Suppl 1):172-179
44. Shen YC, et al. (2013) Activating oxidative phosphorylation by a pyruvate dehydrogenase kinase inhibitor overcomes sorafenib resistance of hepatocellular carcinoma. Br J Cancer 108(1):72-81
45. Lamouille S, Xu J, Derynck R (2014) Molecular mechanisms of epithelial-mesenchymal transition. Nat Rev Mol Cell Biol 15(3):178-196
46. Zeisberg M, Neilson EG (2009) Biomarkers for epithelial-mesenchymal transitions. J Clin Invest 119(6):1429-1437
47. Tsai JH, Yang J (2013) Epithelial-mesenchymal plasticity in carcinoma metastasis. Genes Dev 27(20):2192-2206
48. Miyamoto H, et al. (2004) Tumor-stroma interaction of human pancreatic cancer: Acquired resistance to anticancer drugs and proliferation regulation is dependent on extracellular matrix proteins. Pancreas 28(1):38-44
49. Trédan O, Galmarini CM, Patel K, Tannock IF (2007) Drug resistance and the solid tumor microenvironment. J Natl Cancer Inst 99(19):1441-1454
50. Dephoure N, Gygi SP (2011) A solid phase extraction-based platform for rapid phosphoproteomic analysis. Methods 54(4):379-386
51. Cox J, Mann M (2008) MaxQuant enables high peptide identification rates, individualized p.p.b.-range mass accuracies and proteome-wide protein quantification. Nat Biotechnol 26(12):1367-1372
52. Cox J, Mann M (2012) 1D and 2D annotation enrichment: A statistical method integrating quantitative proteomics with complementary high-throughput data. BMC Bioinformatics 13(Suppl 16):S12-S23
53. Zhang B, Kirov S, Snoddy J (2005) WebGestalt: An integrated system for exploring gene sets in various biological contexts. Nucleic Acids Res 33(Web Server issue): W741-748
54. Huang W, Sherman BT, Lempicki RA (2009) Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc 4(1):44-57